The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with ...

Approximately 1 million Aetna members will need new coverage with the announcement that CVS will be leaving the Affordable ...

Duke Appiah, PhD, MPH, explores racial disparities in maternal health outcomes for pregnant women with cancer, revealing ...

Patients with neovascular age-related macular degeneration (nAMD) experienced improvements in central macular thickness and ...

Experts urge for technology-driven, collaborative solutions as patients shoulder a growing burden of prescription costs.

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to ...

Improving health equity is part of the core of quality improvement and requires data collection and community engagement ...

Infection was a leading cause of death in lower-risk myelodysplastic syndromes (MDS), highlighting the need for vigilant ...

Because clinical trials do not mimic the real-world application of multiple myeloma treatments, Ajai Chari, MD, discussed the variety of patient factors clinicians should consider in their practice.

Experts champion medically integrated care and oncology optimized distribution models as vital strategies to improve outcomes, streamline access, and reduce costs for patients.

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...